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ABSTRACT
The successful demonstration that antiretroviral (ARV) drugs can be used in
diverse ways to reduce HIV acquisition or transmission risks – either taken as
pre-exposure prophylaxis (PrEP) by those who are uninfected or as early
treatment for prevention (T4P) by those living with HIV – expands the arma-
mentarium of existing HIV prevention tools. These findings have implications
for the design of future HIV prevention research trials. With the advent of
multiple effective HIV prevention tools, discussions about the ethics and the
feasibility of future HIV prevention trial designs have intensified.
This article outlines arguments concerning the inclusion of newly estab-
lished ARV-based HIV prevention interventions as standard of prevention in
HIV prevention trials from multiple perspectives. Ultimately, there is a clear
need to incorporate stakeholders in a robust discussion to determine the
appropriate trial design for each study population.
INTRODUCTION
Recent research has expanded the range of safe and effec-
tive HIV prevention modalities from the previously avail-
able behavioural and barrier methods to include
voluntary medical male circumcision (VMMC)1 and
antiretroviral drugs (ARVs) used preventively.2 ARVs
have reduced HIV acquisition when delivered in both
topical and systemic forms,3 and two different strategies
have shown efficacy in particular populations: early treat-
ment for prevention (T4P), which is treatment with ARVs
for HIV-positive partners in HIV-serodiscordant couples
(where one sexual partner hasHIV and the other does not)
before treatment eligibility; and pre-exposure prophylaxis
(PrEP), using ARVs daily or peri-coitally to prevent HIV
acquisition in HIV-negative people at high risk of HIV
acquisition.4 These salutary findings have implications for
the design of future research trials, intensifying discus-
sions about the ethical obligations to provide themand the
1 B. Auvert et al. Randomized, Controlled Intervention Trial of Male
Circumcision for Reduction of HIV Infection Risk: The ANRS 1265
Trial. PLoS Med 2005; 2: e298; R. Bailey et al. Male circumcision for
HIV prevention in young men in Kisumu, Kenya: a randomised con-
trolled trial. Lancet 2007; 369: 643–656; R. Gray et al. Male circumci-
sion for HIV prevention in men in Rakai, Uganda: a randomised trial.
Lancet 2007; 369: 657–666.
2 S.S. Abdool Karim & Q. Abdool Karim. Antiretroviral Prophylaxis:
a Defining Moment in HIV control. Lancet 2011; 378: e23–e25.
3 Q. Abdool Karim et al. Effectiveness and Safety of Tenofovir Gel, an
Antiretroviral Microbicide, for the Prevention of HIV Infection in
Women. Science 2010; 329: 1168–1174; R.M. Grant et al. Preexposure
Chemoprophylaxis for HIV Prevention in Men Who Have Sex with
Men.N Engl JMed 2010; 363: 2587–2599; M.S. Cohen et al. Prevention
of HIV-1 Infection with Early Antiretroviral Therapy. N Engl J Med
2011; 365: 493–505; J.M. Baeten et al. Antiretroviral Prophylaxis for
HIV Prevention in Heterosexual Men and Women. N Engl J Med 2012;
367: 399–410; M.C. Thigpen et al. Antiretroviral Preexposure Prophy-
laxis for Heterosexual HIV Transmission in Botswana. N Engl J Med
2012; 367: 423–434.
4 Grant et al. op. cit. note 3; Cohen et al. op. cit. note 3; Baeten et al. op.
cit. note 3; Thigpen et al. op. cit. note 3.
Address for correspondence: Bridget Haire, Centre for Values, Ethics and the Law in Medicine, University of Sydney, Medical Foundation Building,
Parramatta Road, Camperdown, Sydney, New South Wales 2050 Australia, Email: bridget.haire@sydney.edu.au.
The author has declared a conflict of interest which appears at the end of the article.
Developing World Bioethics ISSN 1471-8731 (print); 1471-8847 (online) doi:10.1111/dewb.12032
Volume 13 Number 2 2013 pp 87–94
bs_bs_banner bioethics
developing world
© 2013 The Authors. Developing World Bioethics published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
Correction added on 30 April 2014 after original publication: The copyright line and license terms have been amended.
feasibility of fulfilling such obligations in resource poor
settings. Specifically, it is critical to consider whether early
T4P or PrEP should be added to the prevention package
for participants in future HIV prevention trials. In
this article, we focus primarily on questions related to
PrEP.
In April 2012, a group of HIV prevention researchers,
policy makers, bioethicists, and advocates participated in
a panel discussion at the Microbicides 2012 conference in
Sydney, Australia. They grappled with some of the con-
siderations that need to inform decisions about the stand-
ard of prevention packages to use in HIV prevention
trials in view of emerging evidence on novel HIV preven-
tion modalities.5 The organisers and some of the pan-
elists, who co-authored this article, came from five
different countries and four continents. This article aims
to reflect that discussion and to extend it with new infor-
mation, including the recent approval of combined daily
oral tenofovir (TDF)/emtricitabine (FTC) as pre-
exposure prophylaxis (PrEP) by the United States Food
and Drug Administration (FDA),6 and the recommenda-
tions from the US Centers for Disease Control and Pre-
vention regarding the use of TDF/FTC for individuals at
high risk of HIV acquisition.7
STANDARD OF CARE
In the setting of clinical trials, ‘standard of care’ is an
umbrella term that describes the care provided to
research participants. In HIV prevention trials the term
has been used to describe at least four different, but
related, considerations. First, it refers to the ‘standard of
prevention’, which is the risk-reduction package provided
to all participants in a trial.8 This package comprises the
measures used to help minimize the risk of HIV infection.
Second, there is ‘ancillary care’, which is health care pro-
vided to trial participants for conditions that are not
directly associated with the research question, such as
contraception and reproductive health care, cervical
cancer screening, and treatment for unrelated illnesses
that arise during trial participation.9 Third, there is
‘standard of care’ regarding HIV treatment that will be
provided to trial participants who seroconvert during the
course of a trial. Fourth, ‘standard of care’ may refer to a
proven effective intervention provided as the comparator
arm in a trial to which the experimental intervention is
compared.10 This article focuses specifically on standard
of prevention.
Both the standard of prevention in trials and the inclu-
sion of a new HIV prevention modality as established
practice in normative guidance and national health poli-
cies have profound impacts on design feasibility and the
ability to interpret HIV prevention trials. In this paper we
outline the tensions associatedwithdetermining the stand-
ard of prevention package for HIV prevention trials.
CURRENT STANDARD OF
PREVENTION PRACTICE
In HIV prevention trials, HIV prevention options cur-
rently offered to participants typically include provision
of male condoms, female condoms on request, HIV
testing and counselling, safer sex counselling, treatment
of sexually transmitted infections (STIs), education and
provision of or referral for VMMC, and access to sterile
injecting equipment.11 In addition, arrangements are
often made to meet participants’ requirements for health
care not directly related to the trial, either through trial
sites or through referral to local health services.
The evidence supporting the use of ARVs for preven-
tion12 raises the pivotal question about whether these new
ARV-based prevention strategies (TDF/FTC PrEP and
early T4P) should be included in the standard of preven-
tion package for HIV prevention trials.
Focusing on the issue of PrEP, we begin with a review
of relevant normative guidance on standards of preven-
tion and care in HIV prevention trials in general. Next,
5 Similar issues have been canvassed in Zaynab, Slack & Koen et al.
HIV prevention responsibilities in HIV vaccine trials: Complexities
facing South African researchers. South African Medical Journal 2010;
100: 45–48.
6 Food and Drug Administration. (FDA). 2012. FDA Approves
First Drug for Reducing the Risk of Sexually Acquired HIV Infection.
(News release) July 16 2012. Silver Spring, MD: FDA. Available
at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/
ucm312210.htm [Accessed 18 Feb 2013].
7 Centers for Disease Control. (CDC). 2012. CDC Issues Interim Guid-
ance on Use of Medication to Prevent HIV Infection among Hetero-
sexually Active Adults. (News release) August 9 2012. Atlanta, GA:
CDC. Available at: http://www.cdc.gov/nchhstp/newsroom/2012/PrEP-
HeterosexualGuidance-PressRelease.html [Accessed 18 Feb 2013].
8 This term was coined in 2007 in the UNAIDS Ethical Considerations
document in hopes of minimizing confusion caused the multiple mean-
ings of ‘standard of care’.
9 H.S. Richardson. Gradations of Researchers’ Obligation to Provide
Ancillary Care for HIV/AIDS in Developing Countries. Am J Public
Health 2007; 97: 1956–1961; L. Belsky & H.S. Richardson. Medical
researchers’ ancillary clinical care responsibilities. BMJ 2004; 328:
1494–1496.
10 R. van der Graaf & J.J.M. van Delden. What is the Best Standard for
the Standard of Care in Clinical Research? The American Journal of
Bioethics 2009; 9: 35–43.
11 L. Heise, K. Shapiro & K. West Slevin. Mapping the Standards of
Care at Microbicide Clinical Trial Sites. Washington, DC: Global Cam-
paign for Microbicides; 2008; B. Haire. 2013. Principal Investigator
Questionnaire on HIV Prevention Trial Standards 2009–2012. (Unpub-
lished) Sydney: University of Sydney.
12 Abdool Karim et al. op. cit. note 3; Grant et al. op. cit. note 3; Cohen
et al. op. cit. note 3; Baeten et al. op. cit. note 3; Thigpen et al. op. cit.
note 3.
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we consider scientific, regulatory, policy and community
perspectives that may inform the question of whether
PrEP ought to be included in the standard of prevention
package. We then apply the guidelines based on such
information.
NORMATIVE FRAMEWORKS
There are two prominent sets of ethical guidelines that
deal specifically with HIV prevention trials: the
UNAIDS/WHO Ethical Considerations in HIV Bio-
medical Prevention Trials13 and the HIV Prevention
Trials Network (HPTN) Ethics Guidance for Research.14
While both guidance documents intend to inform global
HIV prevention research, they were derived by very dif-
ferent groups with unique primary missions; the
UNAIDS guidance was developed by an international
normative agency while the HPTN guidance was
designed by a US-based global network engaged in HIV
prevention research and is accordingly designed to
address some specific needs of the network.15 In some
respects these documents are complementary, but they
differ in the way that they outline the obligations regard-
ing standards of prevention and care.16
Guidance point 13 of the UNAIDS/WHO document
addresses standards of prevention, stipulating that there
is an obligation to provide:
. . . access to all state of the art HIV risk reduction
methods . . . to participants throughout the duration of
the biomedical HIV prevention trial. New HIV-risk-
reduction methods should be added, based on consul-
tation among all research stakeholders including the
community, as they are scientifically validated or as
they are approved by relevant authorities.
This obligation is grounded in the ethical principle of
beneficence. A key intention of the guideline is to prevent
double standards between high- and low- or middle-
income countries, and to be a tool in the progressive
realisation of the right to health. Allowance is made for
negotiation among stakeholders after new prevention
modalities are validated or approved for use by relevant
agencies, with respect to potential impact on feasibility
and the ability to isolate the safety and efficacy of the
biomedical HIV modality being tested.
The HPTN Ethics Guidance takes a somewhat differ-
ent stance, distinguishing between an ethical obligation
and an ethical aspiration. Using this framework, and also
based in the ethical principle of beneficence, guidance
point 9 on the standard of prevention identifies the pro-
vision of an ‘effective’ prevention package for trial par-
ticipants as obligatory. The criteria offered for what
constitutes an effective prevention package is one for
which there is established evidence of efficacy, that is
practically achievable in the trial setting, and that is rea-
sonably accessible. The precise content of that package,
however, is defined as an ‘ethical aspiration’. The com-
mentary states that in certain settings proven risk reduc-
tion methods such as male circumcision may be culturally
inappropriate and others such as needle exchange may be
illegal. It goes on to argue that providing an array of
state-of-the-art risk reduction methods that are not avail-
able outside the trial could constitute undue inducement
to participate. The HPTN document also provides guid-
ance on other aspects of research, including specifying
processes of community engagement, capacity building,
and partnerships.
The HPTN document is structured to address issues
that arise sequentially from before the trial starts to its
conclusion and it identifies stakeholders responsible for
implementing guidance points. In addition, it specifies a
conception of justice in its underpinning principles,
namely ‘social justice’, which is defined as ‘the ethical
concerns related to treating people equally, avoiding
exploitation, and trying to reduce health disparities’.17
Implicitly, this conception focuses on equality between
people inside the trial and people outside the trial in a
local community, in contrast to concerns about reducing
global health disparities between people in high-income
countries and those in low-and middle-income coun-
tries.18 This approach to the standard of prevention
reflects the HPTN document’s genesis as a document
produced for and by a research network. In designating
actions as obligatory or aspirational, the document
13 Joint United Nations Programme on HIV/AIDS (UNAIDS), World
Health Organization (WHO). 2012 (English original 2007, additional
guidance point added 2012). UNAIDS/07.28E/JC1349E Ethical Con-
siderations in Biomedical HIV Prevention Trials. UNAIDS/WHO
Guidance Document. Geneva: UNAIDS and World Health Organiza-
tion. Available at: http://www.unaids.org/en/media/unaids/content
assets/documents/unaidspublication/2012/jc1399_ethical_
considerations_en.pdf [Accessed 18 Feb 2013].
14 S. Rennie, J. Sugarman and the HPTN Ethics Working Group. 2009.
HIV Prevention Trials Network Ethics Guidance for Research. HIV
Prevention Trials Network. Available at: http://www.hptn.org/web%20
documents/EWG/HPTNEthicsGuidanceV10Jun2009.pdf [Accessed 18
Feb 2013].
15 In addition, African countries including South Africa, Kenya and
Uganda have developed their own guidelines for HIV prevention
research. Thanks to an anonymous reviewer for highlighting these
points.
16 Disclosure: one of the authors of this article coordinated the 2007
and 2011 revisions of the UNAIDS/WHO guidance while two authors
were members of the oversight committee producing the 2007
UNAIDS/WHO Guidelines. One of the authors was a primary author
of the HPTN Guidelines.
17 S. Rennie, J. Sugarman and the HPTN Ethics Group, op. cit. note 9,
p. 14.
18 When conducting a study, a principal investigator can address
within-country disparities through cooperation and referral networks
with local health services, but international disparities may be impossi-
ble to address due to major funding and infrastructure deficits.
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intends to help clarify the extent to which particular
guidelines must be met by those responsible for it.19
While the UNAIDS guidelines recommend the adop-
tion of all state-of-the-art risk reduction methods, the
HPTN document takes a less categorical stance. The
rationale for the latter is to guard against people within a
trial having access to a higher standard of prevention
than is available to local communities, which might be
unfeasible to integrate into local health systems.20 This
approach effectively shifts the discourse about double
standards, understood elsewhere to mean disparities
between high-income countries and low- and middle-
income countries, to one that centres on the local com-
munity.21 The UNAIDS recommendation, on the other
hand, supports access to a standard of prevention than
the local community may only aspire to, which can be
justified on the basis that participants bear a greater risk
than other community members by exposure to an unli-
censed product.
Although both documents recommend engagement of
stakeholders in establishing the standard of prevention
packages for trials, the UNAIDS/WHO document states
that the final package should be ‘based on consultation
among all research stakeholders including the commu-
nity’. It also states that the consultative process needs to
take into consideration scientific validation22 of the tools
to be included in the package and whether relevant
authorities have approved the use of such tools for HIV
prevention.23
In addition to these two sets of guidelines, there is a set
of consensus points developed by a group of HIV preven-
tion researchers and bioethicists in 2009 at a ‘Standard of
Prevention’ consultation in Uganda.24 These consensus
points are consistent with the UNAIDS/WHO guidelines
stating that a new intervention is considered ‘state of the
art’ when it is approved by a relevant regulatory authority
or included in normative guidelines. However, they also
encouraged trials already underway (for example,
on-going PrEP trials) to continue, in order to get
maximum information about preventive modalities in
different populations. Further, consensuswas not reached
on the potential role of research to ‘drive or “ratchet up”
the standard of care available in many settings’.25
SCIENTIFIC CONSIDERATIONS
To determine whether PrEP should be integrated into the
standard of prevention, it is necessary to review the rel-
evant scientific information. The cascade of positive trial
results using ARV for HIV prevention began in July 2010
with CAPRISA 004. This trial looked at the efficacy of
1% tenofovir gel formulated as a topical PrEP agent (a
microbicide) for intra-vaginal application before and
after sex. Tenofovir gel reduced the risk of HIV infection
in study participants by 39% when compared to those
using placebo, with a strong correlation between detect-
able drug and observed efficacy, thereby providing the
first indication of the importance of adherence for pro-
tection.26 These results await a confirmatory trial, as
CAPRISA 004 was a test-of-concept trial, not designed
to provide sufficient evidence to support licensure. As
discussed later in this paper, a subsequent trial known as
VOICE that tested daily use of tenofovir gel did not
confirm the results.27 So whether licensure is forthcoming
will depend on the results of a further trial of pericoital
gel use, known as FACTS 001, that commenced in
October 2011.
Four months after the results of CAPRISA 004 were
made known, results from the iPrEx studywere published,
showing that daily oral PrEP, a combination of tenofovir/
emtricitabine (TDF/FTC) in tablet form, reduced HIV
acquisition by 44% in a population of men who have sex
with men (MSM) and transgender women who have sex
with men at high risk of acquiring HIV. Again, efficacy
increasedwith improved adherence to the study product.28
Further evidence showing the efficacy of TDF/FTC as
PrEP came in 2011 from two trials among heterosexual
people in Africa. The Partners PrEP study showed a 75%
reduction inHIV incidence inHIV serodiscordant couples
19 S. Rennie & J. Sugarman. Developing Ethics Guidance for HIV
Prevention Research: the HIV Prevention Trials Network Approach.
J Med Ethics 2010; 36: 810–815.
20 Ibid.
21 S. Rennie, J. Sugarman and the HPTN Ethics Group. op. cit. note 9.
22 For a critique of scientific validation, see B. Haire, J. Kaldor &
C.F.C. Jordens. How Good Is ‘Good Enough’? The Case for Varying
Standards of Evidence According to Need for New Interventions in
HIV Prevention. The American Journal of Bioethics 2012; 12: 21–30.
23 The flexibilities of the UNAIDS/WHO guidance can be seen, for
example, in the decision by the Phambili vaccine trial in Johannesburg
to offer voluntary medical male circumcision (VMMC) without a
national policy being in place in South Africa.
24 S. Philpott, L. Heise & E. McGrory, et al. The challenge of defining
standards of prevention in HIV prevention trials. Journal of Medical
Ethics 2011; 37: 244–248.
25 K. Shapiro & S.R. Benatar. HIV prevention research and global
inequality: steps towards improved standards of care. Journal of
Medical Ethics 2005; 31: 39–47.
26 Abdool Karim et al. op. cit. note 3.
27 Microbicides Trial Network. MTN Statement on Decision to Dis-
continue Use of Oral Tenofovir Tablets in VOICE, a Major HIV Pre-
vention Study in Women. September 28, 2011. Pittsburgh, PA: MTN.
Available at: http://www.mtnstopshiv.org/node/3619 [Accessed 18 Feb
2013].
Microbicides Trial Network. MTN Statement on Decision to Dis-
continue Use of Tenofovir Gel in VOICE, a Major HIV Prevention
Study in Women. Nov 25, 2011. Pittsburgh, PA: MTN Available at:
http://www.mtnstopshiv.org/node/3909 [Accessed 18 Feb 2013].
The TDF/FTC arm in the VOICE trial is continuing, and results are
expected in early 2013.
28 Grant et al. op. cit. note 3; P.L. Anderson et al. Emtricitabine-
Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in
Men Who Have Sex with Men. Science Translational Medicine 2012; 4.
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using combined TDF/FTC, with its tenofovir-only arm
showing a 67% reduction.29 The TDF2 study, conducted
among heterosexual men and women in Botswana,
showed a 62% reduction in HIV acquisition using TDF/
FTC.30
Amidst these positive results are those of two ARV-
based HIV prevention trials that did not demonstrate a
benefit of daily oral TDF/FTC and tenofovir as PrEP: the
FEM-PREP,31 and VOICE32 trials, respectively. In FEM-
PREP, the failure of oral TDF/FTC was linked to poor
adherence, indicated by only 31% of women in the active
trial arm having detectable drug in their blood.33 The
VOICE study also did not demonstrate a protective effect
for the daily use of tenofovir gel or tenofovir-only oral
PrEP and both these arms were stopped for futility.34
Thus, two products that had positive results in other
trials, tenofovir gel in CAPRISA 004 and oral tenofovir
PrEP in Partners PrEP, were unable to be confirmed in
VOICE. Speculation about these conflicting results
includes discussion of the different dosing schedule for gel
use (VOICE used a daily rather than a peri-coital dosing
schedule), and possible adherence issues with the tablet.
Although differences in the populations studied, sexual
behaviours, genital mucosal integrity, and other
co-factors for acquisition may have played a role, low
levels of actual gel or tablet use, resulting in inadequate
genital tract drug concentrations, seems to be the expla-
nation for these divergent trial results.35
The VOICE trial included an arm studying daily oral
TDF/FTC which was also found ineffective.
REGULATORY CONSIDERATIONS
Regulatory authorities that stipulate the level and
strength of evidence required for licensure can have a
considerable impact on trial design. The recent FDA
approval of, and CDC guidance for, the use of daily oral
TDF/FTC PrEP highlight the importance of considering
it when determining the standard of prevention for trials
that include sites in the USA and/or are funded by the US
government. This will be especially complex for multi-
country HIV prevention trials where other nations have
not yet approved PrEP, since they may raise concerns
about interpretability and double standards. Of interest,
the FDA had requested that its Antiviral Advisory Com-
mittee that considered the TDF/FTC application discuss
the implications of approval of TDF/FTC for PrEP for
future placebo-controlled trials. Unfortunately, the Advi-
sory Committee did not have time to undertake such
discussions.36
POLICY CONSIDERATIONS
While the scientific and regulatory questions and issues
are complex, considerations about national policy can
make decision-making about standard of prevention
packages in research even tougher, particularly due to the
time lapse between scientific validation of an intervention
and it being adopted as policy. One case in point is the
Phambili HIV vaccine study that took place in South
Africa and enrolled until September, 2007.37 The trial
included VMMC in the standard of prevention package
offered to male study participants, preceding by three
years the launch of a national VMMC programme in
South Africa in April 2010.38 The decision to include
VMMC in the trial was made on the basis of the scientific
validation of VMMC for HIV prevention.39 By the time
the Phambili trial started, the WHO/UNAIDS had made
a recommendation to adopt VMMC in high incidence
29 Baeten et al. op. cit. note 3.
30 Thigpen et al. op. cit. note 3.
31 L. Van Damme et al. Preexposure Prophylaxis for HIV Infection
among African Women. New Engl J Med 2012; 367: 411–422.
32 Microbicides Trial Network. op. cit. note 24.
33 Van Damme et al. op. cit. note 22.
34 Microbicides Trial Network.MTNStatement onDecision toDiscon-
tinueUse of Oral Tenofovir Tablets in VOICE, aMajorHIV Prevention
Study in Women. September 28, 2011. Pittsburgh, PA: MTN. Available
at: http://www.mtnstopshiv.org/node/3619 [Accessed 18 Feb 2013].
Microbicides Trial Network.MTN Statement on Decision to Discon-
tinueUse of Tenofovir Gel in VOICE, aMajor HIV Prevention Study in
Women. Nov 25, 2011. Pittsburgh, PA: MTN Available at: http://www.
mtnstopshiv.org/node/3909 [Accessed 18 Feb 2013].
The TDF/FTC arm in the VOICE trial is continuing, and results are
expected in early 2013.
35 A. van der Straten, L. Van Damme, J.E. Haberer & D.R. Bangsberg.
Unraveling the divergent results of pre-exposure prophylaxis trials for
HIV prevention. AIDS. 2012 Apr 24; 26(7): F13–F19. The promise of
pre-exposure prophylaxis with antiretroviral drugs to prevent HIV
transmission: a review. C.A. Hankins & M.R. Dybul. Curr Opin HIV
AIDS. 2013 Jan; 8(1): 50–58.
36 See FDA. 2012 Meeting Materials Antiviral Advisory Committee.
May 11 2012 meeting of the Antiviral Drug Advisory Committee Ques-
tions to the committee available at: http://www.fda.gov/downloads/
AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Antiviral
DrugsAdvisoryCommittee/UCM305774.pdf [Accessed 18 Feb 2013];
Transcript of meeting available at: http://www.fda.gov/downloads/
AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Antiviral
DrugsAdvisoryCommittee/UCM311519.pdf [Accessed 18 Feb 2013];
All meeting materials available at: http://www.fda.gov/Advisory
Committees/CommitteesMeetingMaterials/Drugs/AntiviralDrugs
AdvisoryCommittee/ucm295937.htm [Accessed 18 Feb 2013].
37 G. Gray, S. Buchbinder &A. Duerr. Overview of STEP and Phambili
trial results: two phase IIb test-of-concept studies investigating the effi-
cacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine.
Curr Opin HIV AIDS. 2010 Sep; 5(5): 357–361.
38 Treatment Action Campaign (TAC). TAC Briefing on Adult
and Adolescent Voluntary Medical Male Circumcision (VMMC).
Capetown, South Africa:TAC. Available at: http://www.tac.org.za/
community/node/3190 [Accessed 18 Feb 2013].
39 Auvert et al., op. cit. note 1. Bailey et al. op. cit. note 1. Gray et al.
op. cit. note 1.
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countries such as South Africa.40 Had the investigators
waited for the national programme, Phambili partici-
pants would not have had access to a proven effective
intervention. This example shows that it is possible,
where scientific validity is unequivocal, for trial protocols
to adopt interventions as standard of prevention ahead of
national guidelines.
COMMUNITY CONSIDERATIONS
While researchers and research networks differ with
regard to the level and timing of community consultation,
to date many critical decisions made by researchers and
sponsors designing clinical trials have been made well
before the studies commence. At the time of grant
writing, for example, researchers may have identified a
‘high-incidence population’ but not the specific commu-
nities with which the research will take place. This makes
undertaking preparatory work in communities within
tight timeframes very difficult. Therefore guidelines that
require consultation with research stakeholders and com-
munities to help define standard of prevention packages
can entail practical challenges.41 While there are recog-
nised efforts by multiple HIV prevention trial networks
to engage community representatives in dialogue about
the design and implementation of these trials,42 extensive
grassroots consultations prior to conclusion about the
content of the standard of prevention packages for
research may not, and indeed cannot, always occur.43
While some researchers make exceptional efforts to
achieve meaningful community engagement in all aspects
of clinical trial design and implementation, grassroots
consultation in developing countries has its special chal-
lenges due the complexity of randomized clinical trials
and limited understanding of the concepts in the commu-
nity at large. This is further compounded by low levels of
literacy in many resource poor countries44 resulting in
limited participation and contribution of communities
towards meaningful discussions around evolving stand-
ards of care for participants in clinical trials.
Timing is also critical: where researchers consult with
the community after trials have been designed or after
ethics approval of research protocols, community dia-
logue may be limited to simply ensuring successful com-
munity entry and entreating community support and
subsequent ongoing input for project implementation.45
UNAIDS and AVAC developed the Good Participa-
tory Practice guidelines document (GPP) that details
expected engagement processes with communities
throughout the lifecycle of a trial and describes how to
establish mechanisms that give communities opportuni-
ties for input in the research. Such inputs include discuss-
ing the standard of prevention packages.46 The use of the
GPP principles is expanding47 and multiple efforts at pro-
moting their wider use are being undertaken by HIV
prevention research networks.
Even where research has mechanisms to facilitate dia-
logue with community representatives, having communi-
ties negotiate the standard of prevention packages
remains difficult given a myriad of issues that constrain
this practice, including the structural inequalities that
exist between researchers and community members – and
indeed between high- and low-and-middle-income coun-
tries.48 In view of these limitations, standard prevention
packages should be provided in line with clearly defined
guidelines as a responsibility of researchers to the
research participant.49 The utilisation of GPP as a prac-
tice guide in the design and implementation of HIV
prevention research is expected to better systematise com-
munity engagement and promote greater ownership of
research by communities.
The inclusion of PrEP in prevention packages provided
to study participants could build critical service delivery
capacity in the absence of country policies. As a conse-
quence, this might facilitate the development of support-
ive policies and appropriate responses to the results of
40 World Health Organization/UNAIDS. 2007. New Data on Male
Circumcision and HIV Prevention: Policy and Programme Implica-
tions. Montreux, Switzerland. Available at: http://libdoc.who.int/
publications/2007/9789241595988_eng.pdf [Accessed 18 Feb 2013].
41 New HIV Vaccine and Microbicides Advocacy Society (NHVMAS).
2012. Research Community Request For Better Process Of Community
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PrEP demonstration projects. Assuming that trial feasi-
bility is not undermined by trials becoming too expensive
to conduct or difficult to interpret, it can be argued that
the immediate potential benefit of reduced HIV infection
risk for study participants is a legitimate derivable benefit
from the trial for the community, even if this cannot be
sustained beyond the research.50
APPLYING THE GUIDELINES
Given that the USA FDA has approved the use of daily
oral TDF/FTC as PrEP, at first glance the UNAIDS/
WHO ethical guidance would appear to favour its inclu-
sion in the HIV prevention package for future HIV
prevention trials. However, the UNAIDS/WHO guide-
lines indicate that approval must be by relevant authori-
ties.51 Of course, many national regulatory authorities
may hesitate to approve PrEP without WHO recommen-
dations. In this regard, WHO has published guidance on
the use of PrEP in demonstration projects for HIV-
serodiscordant couples and men and transgender women
who have sex with men at high risk of HIV.52 Such dem-
onstration projects are intended to gather further infor-
mation about adherence, HIV testing protocols, drug
resistance and other factors considered key to the devel-
opment of general guidance for implementing PrEP.53
If TDF/FTC PrEP were to be deemed to be part of the
standard of prevention package for HIV prevention
trials, by definition it would need to be offered to all
participants.54 Given its anticipated effects, this would
necessitate larger sample sizes to achieve the same
number of HIV seroconversion endpoints. HIV preven-
tion trials that included a TDF/FTC standard of preven-
tion would therefore be both more expensive and take
longer to reach a conclusion. An example of this design
could be an HIV vaccine efficacy trial in the US. While
the primary comparison would be between the efficacy of
the experimental vaccine and the placebo vaccine, all the
participants in both groups could be offered daily oral
TDF/FTC as part of the risk reduction package. The
sample size would be at least twice as large as it would
have been, had PrEP not been available.55 There are addi-
tional considerations for an HIV vaccine efficacy trial
conducted in resource limited settings. Here, the use of
TDF/FTC as part of the standard of prevention package
could create differences between trial participants and
their communities, particularly where public access to
this drug as part of treatment of HIV is not universal, let
alone for PrEP. This would be considered by many to be
problematic from a social justice perspective, but further
empirical research is required to understand how stand-
ards of prevention affect health care availability and
social dynamics.
The ethical obligation to provide state-of-the-art pre-
vention packages during HIV prevention trials therefore
needs to reconcile the tension between a moral obligation
to ensure optimal protection of and benefits for study
participants, and the imperative to find effective user-
friendly HIV prevention technologies.
MOVING FORWARD
Despite considerable progress in developing safe and
effective means to prevent HIV infection, there remains a
need to develop and test approaches in different popula-
tions. In doing this work, a balance needs to be struck
between prioritising the protection of trial participants
and facilitating ongoing research into new HIV preven-
tion technologies that might prove safer, more accept-
able, less expensive, more effective, and more feasible in
low-and middle-income countries. Not all new options
will be better in all respects (and some might fail), but the
goal is to have a set of options to cover different contin-
gencies. How to facilitate this through research remains
controversial, and is a subject of ongoing debate and
discussion. These debates and discussions emphasize the
difficulty of reaching a consensus on the appropriate
standard of prevention package for HIV prevention trials
for different study populations in different countries.
There is a broad consensus that for all HIV prevention
trials, all study participants should receive a standard
HIV prevention package including male and female
condoms, STI treatment, and behaviour change commu-
nication, as well as education and referral for VMMC in
the instance of heterosexual men who are at particular
50 M. Ukpong, op. cit. note 33.
51 At the time of writing, this issue was under review with regard to the
French trial PrEP Ipergay. Ipergay tests episodic PrEP against a
placebo comparator in men who have sex with men (MSM), and is
being reviewed to determine whether this is ethically appropriate, given
the evidence for PrEP efficacy and the FDA approval. http://
www.ipergay.fr.
52 World Health Organisation. Guidance on oral pre-exposure prophy-
laxis (PrEP) for serodiscordant couples, men and transgender women
who have sex with men at high risk of HIV: Recommendations for use
in the context of demonstration projects. July, 2012. Geneva, Switzer-
land: WHO. Available at: http://www.who.int/hiv/pub/guidance_prep/
en/index.html [Accessed 18 Feb 2013].
53 Ibid.
54 Discussion of alternative trial designs, such as those in which daily
oral TDF/FTC PrEP is used as an active comparator, is beyond the
scope of this article.
55 The HIV Vaccine Trials Network (HVTN) 505 Study currently
taking place in the US is not yet providing oral TDF/FTC for PrEP to
participants, but is offering information about it and monitoring drug
levels. See HVTN 505: Expansion in Response to an Evolving Field.
Seattle, WA: HVTN Available at: http://hvtnews.wordpress.com/2011/
09/13/hvtn-505-expansion-in-response-to-an-evolving-field/ [Accessed
18 Feb 2013].
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risk of HIV exposure.56 However, currently there is no
consensus regarding whether PrEP should be part of the
standard of prevention package in HIV prevention trials
and whether it should be used as a comparator arm.
Decisions by national authorities are not the only factors
to be considered in making this determination, but there
is a lack of a clear decision-making framework at the
international level to clarify whether PrEP should be
included. While there are some conflicting trial results,
the FDA approval of TDF/FTC for the purposes of
PrEP fulfils the ‘scientific validation’ requirement of the
UNAIDS/WHO Guidelines. However, stakeholder
agreement is needed, and the stakeholders – including
regulatory bodies, trial communities, research sponsors
andHIV prevention researchers – have different interests,
perspectives, and levels of influence on the issue.
Reducing and eliminating HIV acquisition is a global
health priority. The goals of HIV prevention research
must be to find the most effective and efficient ways of
using existing tools, including ARV-based prevention,
and to establish the effectiveness of new tools. Ran-
domised controlled trials are an important part of this.
In addition, there is a need for further empirical
research on standard of prevention practices and beliefs
that might inform decision making about whether or how
to include newly validated technologies. Research into
what has been offered at various trial sites to date, how
this was justified (including how various guidelines were
used), and what were the perceived consequences of this
in terms of both short- and long-term health benefits
for trial participants and their communities would be
most valuable to inform ongoing discussions. A pivotal
question is whether higher standards of care for trial
participants eventually ‘ratchet up’ standards in their
communities, or whether such standards promote
inequity.
Determining the appropriate trial design and preven-
tion package for a particular study in a specific HIV risk
population requires careful consideration, taking account
of national and international guidelines, ARV pro-
gramme coverage, and the perspectives of researchers,
ethics committees, trial sponsors, regulators, communi-
ties, and other HIV prevention trial stakeholders. There
is currently no documented evidence on consultative
decision-making processes for defining the standard of
prevention packages for HIV prevention research. The
field needs to develop processes that engage all stake-
holders in realistic and practical decision-making in
a time-sensitive manner, without undue prioritisation of
financial considerations above the interests of trial
participants.
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